The deputy general manager of Tonghua Dongbao resigned.

Guide: The four major domestic enterprises in the field of diabetes (Tonghua Dongbao, Gan Li Pharmaceuticals, Wanbang Biochemical, Zhuhai Federation). on August 10,
, Tonghua Dongbao announced that the company's board of directors received a written resignation report from Han Fengjun, deputy general manager, on August 10th, who applied to resign as the company's deputy general manager for personal reasons.
resigns, Mr. Han will no longer hold any positions in the company. According to public information
, Han Fengjun was born on December 21, 1967, is a senior engineer, practicing Chinese medicine, and graduated from Changchun Chinese Medical College in July 1989.
's main work experience: From July 1989 to May 1990, he was a technician at Tonghua Baishan Pharmaceutical Plant, from May 1990 to May 2007 as a technician, workshop director, chief engineer and deputy general manager of Tonghua Linhai Pharmaceutical Co., Ltd., and from May 2007 to September 2011 He was the Deputy General Manager of Changchun Vande Pharmaceutical Co., Ltd., and from September 2011 to January 2017, he was the Deputy General Manager of Tonghua Jitong Pharmaceutical Co., Ltd., and from February 2017 to May 2018 he was the Technical Director of Tonghua Dongbao, and from May 13, 2018, he was the Deputy General Manager of Tonghua Dongbao.
according to Thesaberg blue combing, nearly a year, Tonghua Dongbao issued a total of 7 personnel changes announced. On May 8,
, Tonghua Dongbao issued independent opinions on the appointment of senior managers by independent directors, and announced a number of personnel appointments - agreeing to appoint Cold Chunsheng as general manager of the company;
June 17, Tonghua Dongbao announced again that the board of directors of the company decided to appoint Su Wei as the company's deputy general manager and secretary of the board of directors, the term of office from the date of the current board of directors to the expiration of the 10th term of the board of directors.
pioneer, the growth rate has slowed public information shows that Tonghua Dongbao was founded on December 1, 1985, headquartered in Tonghua City, Jilin Province, is China's diabetes field pioneer, but also the most complete specifications, the largest second-generation insulin leader, listed in 1994 in the A-share.
, however, its growth rate has slowed in recent years - tonghua Dongbao achieved total revenue of 2.545 billion, 2.693 billion and 2.777 billion yuan in 2017-2019, with yoY growth rates of 24.75 percent, 5.8 percent and 3.13 percent, respectively.
commented that in recent years, due to health insurance control fees, tape procurement, destocking and other reasons, Tonghua Dongbao's performance has declined, the operation has also emerged some problems.
especially the three generations of insulin products market significantly behind their peers, resulting in Tonghua Dongbao forced from the "first" to "catcher."
, according to Tonghua Dongbao's 2019 financial results, achieved total revenue of 2.78 billion yuan, up 3.1% YoY, and realized a net profit of 810 million, down 3.3% YoY, mainly due to factors such as single-generation and third-generation insulin competition, and management actively destocked channels from the third quarter of 2018, resulting in a decline in the growth rate of the second-generation insulin business.
model, layout rich pipeline 2019 financial results show that Tonghua Dongbao's main business for the pharmaceutical industry, real estate industry, building materials industry, accounting for 94.93 percent, 4.0%, 0.18% of revenue, respectively - in order to focus more on the diabetes sector, Tonghua adjusted the product structure in 2019, real estate business revenue ratio from 11.83% in 2018 to 4.04%.
product segmentation: In 2019, Tonghua Dongbao recombined human insulin apiandic drugs and injection products to achieve a total revenue of 2.214 billion yuan, accounting for 80.45 percent of total revenue, up 14.09 percent year-on-year, gross margin of 84.09 percent, down 2.63 percent year-on-year.
among them: preparation revenue of 2.102 billion yuan (11.8%), sales of about 54.02 million units (14.87%), raw materials revenue of 113 million yuan (84.58%), overall gross Interest rates fell slightly, and medical devices such as injection pens, blood glucose test papers and blood needles achieved revenue of 355 million yuan, up 8.71% YoY, while revenue from other businesses, including pharmaceuticals, plastic steel windows and profiles and real estate businesses, all showed a decline of varying degrees.
According to Minnet data, in 2019 China's public medical institutions and retail pharmacies total diabetes market size of 69.59 billion yuan.
sales of public health facilities grew at a steady rate of 12.8% in 2013-2019.
domestic diabetes competitors, including three multinational pharmaceutical companies (Novo Nordisk, Sanofi, Lilly) and four domestic enterprises (Tonghua Dongbao, Ganli Pharmaceuticals, Wanbang Biochemical, Zhuhai Federation).
good, the current Tonghua Dongbao research and development pipeline is very rich, through the model of imitation combination of three generations of insulin (glycol, mendong, Lai, die), four generations of insulin (BC overspeed effects and meal combination), GLP-1, OAD and other product portfolio.
from the development progress, 2020-2025, Tonghua Dongbao will usher in a product market intensive harvest period - among which, 2022-2023 Mendong insulin 50/30 is expected to be marketed and the heavyweight variety GLP-1 lilalutide to be listed around 2023.
in the 2019 Annual General Meeting Of Shareholders' Meeting, Tonghua Dongbao said it will focus on the development and production of drugs around the diabetes field to accelerate the pace of transformation of results.
continuously adjust the marketing mechanism to enhance the company's operating performance.
.